Donepezil is a noncompetitive acetylcholineesterase inhibitor, which can readily cross the blood brain barrier and increase the concentration of cortical acetylcholine. It is known that Donepezil is a useful tool in the study of Alzheimer's disease. Studies indicate that Donepezil protects the brain against diisopropylfluorophosphate-induced effects. Studies indicate that Donepezil selectively inhibits acetylcholineesterase, whereas it has little effect on butyrylcholinesterase. Alternate studies suggest that Donepezil increases the concentration of extracellular acetylcholine in the cerebral cortex and hippocampus of rats.
1. Shintani, E.Y., et al. 1997. Am J Health Syst Pharm. 54: 2805-2810. PMID: 9428950 2. Bryson, H.M. and Benfield, P. 1997. Drugs Aging. 10: 234-240. PMID: 9108896
Soluble in chloroform (~50 mg/ml), and acetone (~25 mg/ml).
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
Bryson et alBryson et al. (PubMed ID 9108896) found that Donepezil inhibited acetylcholinerase activity in human red blood cells and increased acetylcholine in the cerebral cortex and hippocampus of rats. It was also used to improve cognitive function in patients with Alzheimer s disease. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn